WELCOME TO The PHARMACEUTICAL REPORT
Esperion - The Lipid Management Company
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Ligand Pharmaceuticals | December 22, 2021
Ligand Pharmaceuticals Incorporated announced today the expansion of an existing collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline. The expansion will leverage Icagen’s ion-channel-based discovery technology and unique expertise in small molecule therapeutics targeting transmembrane proteins. This new agreement builds upon the initial December 2020 agreement to identify and develop inhibitors of a specific genetically-validated molecular target relevan...
CareRx | January 18, 2021
CareRx Corporation ("CareRx" or the "Company") (TSX: CRRX), Canada's leading provider of specialty pharmacy services to seniors, is pleased that the Ontario Ministry of Health has announced that it will pause for one year previously scheduled changes to long-term care pharmacy funding, which were scheduled to go into effect on April 1, 2021.
Under certain amendments to the Ontario Drug Benefit Act that came into effect on January 1, 2020, the reimbursement ...
DCAT Value Chain Insights | February 05, 2020
Small molecules still lead over biologics in recent drug approvals, accounting for nearly three-fourths of drug approvals over the past several years, but will small molecules' dominance continue? DCAT Value Chain Insights takes an inside look. One measure to evaluate the role of small molecules versus biologics is to look how they have fared in recent approvals of new molecular entities (NMEs) by the US Food and Drug Administration’s Center for Drug Evaluation and Research. Between 20...
Asymchem | September 17, 2021
Asymchem today announced a strategic partnership agreement to provide LaNova Medicines with one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration.
The collaboration between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives. This partnership will take full advantage of Asymchem's recently co...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE